

Pyoderma gangrenosum after cesarean section treated with skin graft

A case report

Jinjing Shen, MD, Weishe Zhang, MD, Xiaoe Jiang, MD*

Abstract

Rationale: Pyoderma gangrenosum (PG) is a rare skin disease. Pregnancy is a unique physiological condition. Here we report a rare case of PG after cesarean section.

Patient concerns: A 32-year-old female presented with wound breakdown 1 day after cesarean section, with progression to a skin ulcer and no response to antibiotic therapy.

Diagnoses: We experienced a case of PG after cesarean section. This was initially misdiagnosed as a wound infection, with fever and wound redness as clinical manifestations.

Interventions: The patient was initially treated with antibiotics, followed by glucocorticoid and human immunoglobulin therapy. Wound debridement, vacuum sealing negative pressure drainage, skin grafting, and hyperbaric oxygen therapy were also performed.

Outcomes: The wound healed without adverse reactions.

Lessons: When a surgical incision infection does not respond to antibiotic treatment and the culture is negative, PG should be considered.

Abbreviations: CRP = C-reactive protein, IL = interleukin, PCT = procalcitonin, PG = pyoderma gangrenosum, TNF = tumor necrosis factor.

Keywords: caesarean section, pyoderma gangrenosum, skin graft

1. Introduction

Pyoderma gangrenosum (PG) is a type of dermatitis with a very low incidence, and is characterized by dermal neutrophilic infiltration and destruction.^[1] The cause is still unclear, but the disease may be associated with neutrophil dysfunction, release of inflammatory mediators, or genetic susceptibility.^[2] PG is usually characterized by scattered lesions in the limbs, with pustules and ulceration after lesion enlargement. PG forms a clear, insidious, blue-edged painful ulcer, with satellite-like purple papules, and usually presents without fever. PG lesions can be ulcerative, pustular, bullous, or proliferative.^[3] The pathological damage in the skin presents as necrosis and

Editor: N/A.

Medicine (2019) 98:18(e15380)

Received: 28 November 2018 / Received in final form: 20 March 2019 / Accepted: 2 April 2019

http://dx.doi.org/10.1097/MD.000000000015380

ulceration in the central epidermis and dermis, with dense infiltration of various inflammatory cells around the ulcer; however, the pathological manifestations are not characteristic. PG may be associated with a variety of systemic diseases, including inflammatory bowel disease, rheumatoid arthritis, and hematological malignancies.

Pregnancy is an immunosuppressed state, and pregnant women are susceptible to infection. The incidence of PG in pregnancy is extremely low, and the occurrence of PG after cesarean section is even rarer, with only 17 cases reported worldwide between 1996 and 2019,^[4] among which only one was treated with surgery. We report a case of PG after cesarean section. Treatment included glucocorticoid therapy and surgery.

2. Case

A 32-year-old G_8P_1 female with no significant medical history was admitted to a hospital in Changsha for "lower abdominal pain more than 1 day" on September 12, 2017, at >7 months of gestation. Premature rupture of membranes occurred. Ultrasound showed "placental abruption," and emergency cesarean section was performed. On postoperative day 2, the patient developed a fever to 42°C. Local swelling and redness developed, with gradual progression to skin ulceration at the incision site. Wound secretion culture was negative for group B *Streptococcus*. The postoperative placental pathological diagnosis was stage I acute chorioamnionitis. Cefoperazone sulbactam, doxycycline, roxithromycin, imipenem, vancomycin, ornidazole, and other antibiotics were successively given for infection. However, the patient's condition did not improve.

The authors have no funding and conflicts of interest to disclose.

Department of Obstetrics, Xiangya Hospital, Central South University, Changsha, Hunan, China.

^{*} Correspondence: Xiaoe Jiang, Department of Obstetrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan 410000, China (e-mail: jxesjj@outlook.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.



Figure 1. Pyoderma gangrenosum after cesarean section treated with skin graft 14 months later

An outside consultation was requested. By September 21, the patient had developed an incisional skin defect of about 25×15 cm, extending deep to the anterior sheath of the rectus abdominis, with extensive yellow-white necrotic tissue and liquefied adipose tissue visible on the wound surface; there was extensive redness, swelling, and blistering of skin around the wound, with scattered purulent areas. PG was considered and the patient was treated with intravenous methylprednisolone 80 mg and human immunoglobulin 10,000 mg. After 1 day of glucocorticoid treatment, the patient's fever decreased and the wound showed no further deterioration.

Due to a "large abdominal skin lesion," the patient was admitted to the burn unit of our hospital on September 22. Blood tests after admission showed a white blood cell (WBC) count of 23.4×10^9 /L (neutrophils, 95.2%); red blood cell (RBC) count of 3.33×10^{12} /L; hemoglobin of 96.0 g/L; platelet count of 286.0×10^9 /L; and albumin of 33.1 g/L, but no renal function abnormalities. The patient was treated with linezolid combined with levofloxacin and metronidazole. Continuous methylprednisolone, immunoglobulin, and other immune therapy were administered. Wound debridement was performed and vacuum sealing negative pressure drainage (VSD) was initiated on September 22.

On September 23, blood tests were as follows: WBC, $18.7 \times$ 10^{9} /L (neutrophils, 90.8%); RBC, 3.07×10^{12} /L; hemoglobin, 90.0 g/L; platelets, 343.0×10^{9} /L; procalcitonin (PCT), 0.21 ng/ mL; C-reactive protein (CRP), 76.0 mg/L; and albumin, 28.9 g/L. The antibiotic treatment regimen was adjusted, with substitution of minocycline. After 2 days of glucocorticoid therapy, the infection index began to decrease and the wound surface showed no further expansion. Blood tests on September 25 were as follows: WBC, 10.1×10^{9} /L (neutrophils, 75.8%); RBC, $3.4 \times$ 10^{12} /L; hemoglobin, 100.0g/L; platelets, 365.0×10^{9} /L; PCT, <0.05 ng/mL; CRP, 19.3 mg/L; interleukin (IL)-1β, 41.0 pg/mL; tumor necrosis factor (TNF)-α, 26.2 pg/mL; IL-6, 10.6 pg/mL; and IL-10, 12.0 pg/mL. No bacterial growth was observed on wound tissue culture. Human immunoglobulin was discontinued and cyclosporine A was added on September 26. Incision debridement and VSD were repeated on September 26.

Further debridement and skin grafting were performed on October 9. Histopathological analysis of debrided tissue (abdominal incision) showed suppurative inflammation with necrosis, but no clear evidence of fungal infection. Periodic acid-Schiff (PAS) and PAS-diastase staining was negative. The patient was discharged on October 19, 2017, with the following results: IL-1 β , 52.7 pg/m; TNF- α , 2.0 pg/mL; IL-6, 2 pg/mL; and IL-10, <5.00 pg. Routine blood tests, CRP, PCT, and other infection indicators gradually returned to normal, the necrotic wound tissue receded, and the cesarean section wound healed.

After discharge, the patient regularly returned to the dermatology clinic for treatment. She continued prednisone 40 mg daily and cyclosporine 50 mg 3 times a day, and gradually reduced the dosage; treatment was stopped in October 2018, and the wound completely healed (Fig. 1).

3. Discussion

Among reported PG cases during pregnancy,^[5–12] including the gestational and postpartum periods, >50% had occurred at the cesarean section incision. Some case reports described PG lesions on the limbs, the abdomen, and the axilla during pregnancy, with resolution in 2 cases after cesarean section. Postoperative follow-up revealed no lesions at the cesarean section incision. This result may be due to glucocorticoid and cyclosporine treatment.

PG involving a cesarean incision typically presents with painful erythema at the incision site. Wound dehiscence can occur or punctate surface ulcers may develop in the erythematous area, eventually coalescing into a deep-seated ulcer running along the wound margin. In contrast with cases unrelated to pregnancy, patients who develop PG after cesarean section often present with fever as the initial symptom. The first symptom in the present case was fever. The intraoperative placental pathological examination suggested chorionic inflammation. The patient had a prolonged course of recurrent fever postoperatively, and the wound ulceration rapidly evolved. Such clinical manifestations can lead to misdiagnosis as a surgery-associated infection. In some reported cases,^[13–15] tests for lupus, immune factors,

In some reported cases,^[13–13] tests for lupus, immune factors, rheumatoid factor, and anti-double-stranded DNA were all negative, and bacterial growth was not observed in wound culture. Pathological evaluation mostly showed inflammation and vascular necrosis. The lack of specific diagnostic markers makes early identification of PG in pregnancy difficult. PG remains a diagnosis of exclusion. Neutrophils in patients with skin involvement by PG can also infiltrate the heart, lungs, and digestive tract, leading to multiple organ dysfunctions. Hence, screening for autoimmune disease, aseptic inflammatory disease, and others should be performed.

Pregnancy, as a unique, immunosuppressed pathological state, is characterized by IL-2 inhibition and IL-1 activation, as well as decreased polymorphonuclear leukocyte chemotaxis and adhesion.^[16] These changes in maternal immune function may play an important role in the occurrence and development of PG in pregnancy.

In the present case, TNF- α , IL-1, and IL-6 were significantly increased, possibly in association with activation of inflammatory pathways during pregnancy and initiation of labor, or activation of granulocyte colony factors. The reason for neutrophil dysfunction in PG is not clear, but may result from direct or indirect causes, such as enhanced expression of inflammatory factors, including TNF- α , IL-1b, and IL-8.^[17] An increase in TNF-α, IL-6, and IL-1 is known to be associated with tumors, autoimmune diseases, severe inflammatory reactions, and graft rejection. TNF- α inhibitors are reportedly effective in treating PG induced by chronic inflammatory bowel disease.^[3,18,19] This suggests that TNF- α , IL-1, and IL-6 may be specific markers for PG. When TNF- α , IL-1, and IL-6 continue to increase, and the extent of the increase is not consistent with that of infection-related indicators, a diagnostic trial of glucocorticoid and other immunosuppressive therapies should be considered. This may have important implications for early identification and intervention in PG.

In patients with PG, the wound is painful and fissured, similar to the typical presentation of necrotizing fasciitis. Based on the clinical manifestations, acute wound infection is usually the first diagnosis, but antibiotics used empirically will be ineffective. Therefore, when antibiotics fail to treat the wound, and the wound culture is negative, PG should be considered, with timely adjustment of the treatment plan.

There is currently no standard protocol for the treatment of PG. Treatment methods divided into medications and surgery. Medication is given systemically or topically. As PG can present with systemic involvement, concurrent treatment of the primary disease is necessary. The first-line drug for PG is glucocorticoid, while cyclosporine A, mycophenolate,^[20] and TNF inhibitors are second-line drugs. Intravenous immunoglobulin has also been successfully used in the treatment of PG. Cases treated with alefacept, visilizumab, anakinra, and even tacrolimus have been reported.^[4] Drug treatment requires assessment of liver and renal function, and cyclosporine A is not recommended in severe renal insufficiency. Surgical treatment is controversial in PG. Local debridement may cause secondary injury, which prevents wound healing and can accelerate the deterioration and expansion of the wound by recruiting neutrophils. One case report^[11] discussed flap transplantation for PG that developed in pregnancy, with a satisfactory outcome.

In this case, the patient was hospitalized for 35 days; this duration was less than that reported for similar cases in China and other countries. When the diagnosis of PG is considered, systemic glucocorticoid treatment should be given. After the lesion is effectively controlled, surgical treatment can be scheduled, and greatly enhances the speed of wound healing. Hyperbaric oxygen therapy can then be given to further promote wound healing. Combined drug and surgical treatment can effectively reduce the patient's economic and social burden.

4. Conclusion

Due to the low incidence of PG after cesarean section and the lack of specific diagnostic indicators, the diagnosis is extremely difficult. The misdiagnosis rate is high, and there is still lack of guidance for treatment, requiring multidisciplinary collaboration. Early identification, timely intervention, and long-term management are the keys to therapy in PG after cesarean section.

Author contributions

Resources: Weishe Zhang.

Writing – original draft: Jinjing Shen.

Writing - review and editing: Xiaoe Jiang.

References

- Crowson AN, Mihm MCJr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003;30:97–107.
- [2] Bhat RM, Nandakishore B, Sequeira FF, et al. Pyoderma gangrenosum: an Indian perspective. Clin Exp Dermatol 2011;36:242–7.
- [3] Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol 2009;10:301–12.
- [4] Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol 2011;23:50–6.
- [5] Steadman UA, Brennan TE, Daman LA, et al. Pyoderma gangrenosum following cesarean delivery. Obstet Gynecol 1998;91(5 Pt. 2):834–6.
- [6] Park JY, Lee J, Park JS, et al. Successful vaginal birth after prior cesarean section in a patient with pyoderma gangrenosum. Obstet Gynecol Sci 2016;59:62–5.
- [7] Cokan A, Dovnik A, Zebeljan I, et al. Pyoderma gangrenosum in a caesarean wound following caesarean section with late occurrence of pyoderma gangrenosum of the breast. Eur J Obstet Gynecol Reprod Biol 2016;203:343–4.
- [8] Ronnau AC, von Schmiedeberg S, Bielfeld P, et al. Pyoderma gangrenosum after cesarean delivery. Am J Obstet Gynecol 2000;183: 502–4.
- [9] Satoh M, Hiraiwa T, Yamamoto T. Recurrent pyoderma gangrenosum developed after a cesarean section with a 10-year interval. Int J Dermatol 2018;57:e92–3.
- [10] Nonaka T, Yoshida K, Yamaguchi M, et al. Case with pyoderma gangrenosum abruptly emerging around the wound of cesarean section for placenta previa with placenta accrete. J Obstet Gynaecol Res 2016;42:1190–3.
- [11] Aydin S, Aydin CA, Ugurlucan FG, et al. Recurrent pyoderma gangrenosum after cesarean delivery successfully treated with vacuumassisted closure and split thickness skin graft: a case report. J Obstet Gynaecol Res 2015;41:635–9.
- [12] Banga F, Schuitemaker N, Meijer P. Pyoderma gangrenosum after caesarean section: a case report. Reprod Health 2006;3:9.
- [13] Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23:1008–17.
- [14] Amin SV, Bajapai N, Pai A, et al. Pyoderma gangrenosum in two successive pregnancies complicating caesarean wound. Case Rep Obstet Gynecol 2014;2014:654843.
- [15] Nanoudis S, Tsona A, Tsachouridou O, et al. Pyoderma gangrenosum in a patient with chronic granulomatous disease: a case report. Medicine (Baltimore) 2017;96:e7718.
- [16] Radhika AG, Singal A, Radhakrishnan G, et al. Pyoderma gangrenosum following a routine caesarean section: pseudo-infection in a caesarean wound. Qatar Med J 2015;2015:1.
- [17] Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 2015;73:691–8.
- [18] Sockolov ME, Alikhan A, Zargari O. Non-psoriatic dermatologic uses of monoclonal antibody therapy. J Dermatolog Treat 2009;20: 319–27.
- [19] Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010;62: 646–54.
- [20] Li XL, Ma ZG, Huang WH, et al. Successful treatment of pyoderma gangrenosum with concomitant immunoglobulin A nephropathy: a case report and review of literature. World J Clin Cases 2018;6:703–6.